Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Background To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer.Methods Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durvalum...
Main Authors: | Carol I Geppert, Arndt Hartmann, Benjamin Frey, Markus Eckstein, Markus Hecht, Antoniu Oreste Gostian, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Matthias G Hautmann, Gunther Klautke, Simon Laban, Thomas Brunner, Axel Hinke, Ina Becker, Sabine Semrau, Panagiotis Balermpas, Wilfried Budach, Heinrich Iro, Rainer Fietkau |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e001378.full |
Similar Items
-
Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy
by: Carol I Geppert, et al.
Published: (2020-07-01) -
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer
by: Sabine Semrau, et al.
Published: (2021-04-01) -
Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
by: Syed S. Mahmood, et al.
Published: (2018-08-01) -
A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
by: Michal Sarfaty, et al.
Published: (2021-02-01) -
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
by: Houda Bahig, et al.
Published: (2019-01-01)